Susana Inmaculada Inoges Sancho-rekin lankidetzan egindako argitalpenak (7)

2023

  1. Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

    Biomedicines, Vol. 11, Núm. 2

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

2021

  1. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

2019

  1. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2008

  1. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

    European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586

2000

  1. Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure

    Cardiovascular Pathology, Vol. 9, Núm. 3, pp. 153-159